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 CURRENT
OPINION Atypical parkinsonism: an update
Maria Stamelou
a,b,c and Guenter U. Hoeglinger
d,e
Purpose of review
This update discusses novel aspects on genetics, diagnosis, and treatments of atypical parkinsonism
published over the past 2 years.
Recent findings
A genome-wide association study identified new genetic risk factors for progressive supranuclear palsy and
new genetic conditions presenting with atypical parkinsonism have been described. The clinical criteria for
diagnosis of corticobasal degeneration have been revised, and for progressive supranuclear palsy are
under revision. Novel molecular techniques to identify possible biomarkers, as in other neurodegenerative
disorders, have started being studied on atypical parkinsonian conditions, and although preliminary results
seem promising, further studies are urgently warranted. Therapeutic trials based on disease-specific targets
have shown no clinical improvement.
Summary
The knowledge obtained recently on atypical parkinsonian conditions points out the major deficits in this
field. With the expanding phenotypical spectrum of atypical parkinsonian conditions, the early
identification of patients has become difficult. The inability of conventional methods to identify these
disorders earlier and better than clinicians, and the recent failure of promising therapeutic compounds,
highlight the fact that the lack of biomarkers is probably the greatest limitation for developing treatments for
these disorders. Thus, current and future research in this direction will be crucial.
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INTRODUCTION
Atypical parkinsonian conditions comprise mostly
progressive supranuclear palsy (PSP), corticobasal
degeneration (CBD), multiple system atrophy
(MSA), and dementia with Lewy bodies (DLB). Apart
from these sporadic neurodegenerative disorders,
atypical parkinsonism has also been described in a
variety ofother heredodegenerative conditionssuch
as frontotemporal dementia (FTD), Alzheimer’s dis-
ease, and Perry syndrome. With the recent advent in
genetics, these disorders are constantly increasing
[1].
Despite decades of research, the cause and path-
ophysiology of atypical parkinsonian disorders are
still unknown. Moreover, the early differential diag-
nosis of patients with atypical parkinsonism, which
would be important for clinical (e.g., prognosis and
treatment) and research purposes, is poor. Thera-
peutic options are still limited. However, in recent
years, there have been some new insights into atyp-
ical parkinsonian conditions regarding genetic,
diagnostic, and treatment aspects, which will be
discussed in this review.
UPDATE ON GENETICS
Recently, the first genome-wide association study
(GWAS) has been performed in PSP to identify genes
that modify risk for this primary tauopathy. Apart
from confirming two independent variants in
MAPT affecting risk for PSP, this study identified
three significant novel signals associated with
PSP risk, which may give some insight into the
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pathophysiology of the disease. One is at EIF2AK3, a
gene encoding PERK, which is a component of the
endoplasmic reticulum (ER) unfolded protein
response (UPR). When excess unfolded proteins
accumulate in the ER, PERK is activated and protein
synthesis is inhibited allowing the ER to clear mis-
folded proteins. However, tau, which is the primary
misfolded protein in PSP, is not expected to traffic
through the ER. The second PSP susceptibility gene,
STX6, encodes syntaxin 6, and it is hypothesized
that genetic variation at STX6 may influence move-
ment of misfolded proteins from the ER to lyso-
somes via the endosomal system. Finally, the
third locus is the MOBP gene, which encodes a
protein (MOBP) that is produced by oligodendro-
cytesandispresentinthemajordenselineofcentral
nervous system (CNS) myelin. MOBP is highly
expressed in the white matter of the medulla, pons,
cerebellum, and midbrain, regions affected in PSP,
suggesting that myelin dysfunction or oligodendro-
cyte misfunction may contribute to PSP pathogen-
esis [2]. However, further research is needed to
understand how these loci are related to PSP path-
ophysiology. For MSA, small studies in the past have
suggested some possible loci, with the strongest
being alpha-synuclein variations (SCNA) [3]; how-
ever, a GWAS is currently underway.
Familial MSA has been reported rarely. Whole-
genomesequencing and linkage analysis of asample
obtained from a member of a multiplex family in
whomMSAhadbeendiagnosedonautopsyrevealed
a homozygous mutation (M78V–V343A/M78V–
V343A) and compound heterozygous mutations
(R337X/V343A) in COQ2 in two multiplex families
[4]. COQ2 encodes parahydroxybenzoate-poly-
prenyl transferase, which is essential for the biosyn-
thesis of coenzyme Q10. Furthermore, the authors
found that a common variant (V343A) and multiple
rare variants in COQ2, all of which are functionally
impaired, were associated with sporadic MSA [4].
This study needs to be further confirmed by
independent studies.
In recent years, there has been tremendous
research on genetic forms of frontotemporal lobar
degeneration (FTLD), which has identified genes
that may present with atypical parkinsonism, and
in some cases also mimicking PSP, CBD, or MSA [1].
For example, microtubule-associated protein tau
(MAPT) and progranulin (PGRN) gene mutations
[tau and TAR DNA-binding protein-43 (TDP-43)
pathology, respectively], both inherited in a
dominant pattern, are known to cause atypical
parkinsonism [1]. However, a major recent break-
through in the genetics of FTLD and amyotrophic
lateral sclerosis has been the identification of hex-
anucleotide expansions in chromosome 9 open
reading frame 72 (C9ORF72) gene (TDP-43 patho-
logy), which classically cause FTD–amyotrophic
lateral sclerosis overlap syndromes [5
&&,6
&&]. How-
ever, 35% of these patients may also have atypical
parkinsonism, and cases with slowness of vertical
saccades, parkinsonism, frontal dementia, and
abnormal DaTSCANs, mimicking PSP but also cor-
ticobasal syndrome (CBS), have been reported
[5
&&,6
&&,7–10]. One study has screened a large popu-
lation of patients with atypical parkinsonism and
found this mutation to be rare in apparently spora-
dic patients with PSP, CBS, and MSA [11
&&]. In a
furtherstudy,3.2%ofpatientswithaPSPphenotype
carried the mutation [12
&&]. Apart from the genes
causing FTLD, further genetic disorders presenting
with atypical parkinsonism have been increasingly
recognized [1,13].
UPDATE ON DIAGNOSTICS
The following section summarizes advances in
clinical, imaging, and nonimaging diagnostics and
new possible candidates that may serve as bio-
markers for these disorders.
Clinical criteria
Pathologyremainsthegoldstandardfordefinitediag-
nosis for PSP, CBD, MSA, and DLB. For clinical diag-
nosis, diagnostic criteria have been widely used;
however,thesehaveneverbeenverifiedprospectively
and there is a need for independent clinicopatholog-
ical confirmation. Recently, a clinicopathological
evaluation of the NINDS-SPSP (National Institute of
Neurological Disorders and Stroke and Society for
Progressive Supranuclear Palsy) [14] vs. NNIPPS (the
Neuroprotection and Natural History in Parkinson
Plus Syndromes) [15] criteria was conducted on 98
PSP patients and demonstrated that the NINDS-SPSP
‘probable’ criteria yielded shorter time to diagnosis,
KEY POINTS
  A GWAS study in PSP has identified new loci possibly
related to the disease pathophysiology, while in MSA a
GWAS is underway.
  New clinical criteria are proposed for CBD and are
under revision for PSP.
  New possible candidates are currently being evaluated
as possible biomarkers for atypical
parkinsonian condition.
  Recent therapeutic trials in PSP have failed to show any
clinical benefit, and this indicates the urgent need for
identification of biomarkers in these disorders.
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slightly higher specificity and positive predictive
value, and similar sensitivity, compared with the
NNIPPS criteria, whereas a combination of NINDS-
SPSPpossibleandprobablecriteriayieldedthehighest
sensitivity. Thus, it is suggested that the NINDS-SPSP
probablecriteriamightbepreferredforrecruitmentof
patientsforclinicaltrials,whereasforroutineclinical
care, a combination of NINDS possible and probable
criteria might be preferred [16
&]. However, there is
currently a Movement Disorders Society Task Force
undertaking revision of the PSP clinical criteria.
Also, new diagnostic criteria for CBD have been
proposed. In this study, clinical diagnoses were
identified for 267 nonoverlapping pathologically
confirmed CBD cases from published reports and
brain banks [17
&]. Four CBD phenotypes emerged:
CBS, frontal behavioral-spatial syndrome, nonflu-
ent/agrammatic variant of primary progressive
aphasia, and PSP syndrome, which has also been
confirmed by another independent study [18
&].
Clinical CBD phenotypes and features were com-
bined to create two sets of criteria: more specific
clinical research criteria for probable CBD and
broader criteria for possible CBD that are more
inclusive but have a higher chance to detect other
tau-based diseases [17
&]. However, future validation
and refinement of the proposed criteria are needed.
Structural and functional imaging
Several abnormalities in MRI have been proposed in
the past as possible candidates to differentiate
between atypical parkinsonian syndromes [19].
However, their sensitivity and specificity had not
been confirmed in pathologically proven cases. MR
images from 48 neuropathologically confirmed
cases, including PSP (n¼22), MSA (n¼13), Parkin-
son’s disease (n¼7), CBD (n¼6), and controls
(n¼9) were assessed retrospectively in one study
and it was found that the clinical diagnosis was
more sensitive in PSP (90.9% in PSP compared with
72.7% in MSA) and the radiological diagnosis more
sensitive in MSA (61.5% in PSP compared with
76.9% in MSA) [20]. The radiological diagnosis
was more specific than the clinical diagnosis in both
PSP and MSA, and radiologically no case of MSA was
classified as PSP or vice versa. The most clinically
useful abnormalities seen in PSP were signs of mid-
brain atrophy (86.4%), superior cerebellar peduncle
atrophy, and frontal and parietal cortical atrophy.
The ‘morning glory flower sign’ and the ‘humming
bird sign’ were very specific but with a low sensi-
tivity (50 and 68.4%, respectively). In MSA, only
50% had putaminal atrophy and 25% the hyper-
intense putaminal rim. Middle cerebellar peduncle
hyperintensity was found in 50.0% of the MSA
patients, and the hot cross bun sign in 58.3%
[20]. These findings suggest that better and novel
MRI techniques are needed to improve sensitivity
and to be able to serve as specific biomarkers for
monitoring disease progression.
Functional imaging has been used in the differ-
ential diagnosis of parkinsonism. One recent study
showed that sensitivity/specificity of [
18F]FDG-PET
(F-18 fluorodeoxyglucose positron emission tom-
ography) in identifying atypical parkinsonian sub-
groups was 77/97% for MSA, 74/95% for PSP, and
75/92% for CBD (clinically diagnosed patients) [21].
In another study, 136 parkinsonian patients under-
went [
18F] FDG-PET and the results were compared
to a 2-year follow-up of clinical assessment. Con-
cordance of visual evaluation of [
18F] FDG-PET with
clinical diagnosis was achieved in 80% MSA, 76.6%
PSP, and 100% CBS patients. Blinded computer
assessment using statistical parametric mapping
was concordant with the clinical diagnosis in 80%
MSA, 93.3% PSP, and 100% CBS patients [22],
suggesting its possible usefulness in the differential
diagnosis of these disorders.
Novel diagnostic approaches
Research has focused in recent years on possible
novel molecular biomarkers for atypical parkinso-
nian conditions [23,24]. Studies on specific proteins
in cerebrospinal fluid (CSF) have shown some pre-
liminary but often contradictory results: CSF alpha-
synuclein levels in MSA have been reported to be
decreased compared with controls (but not with
Parkinson’s disease patients) [24,25
&&], but normal
in another study [26]. In PSP and CBD, CSF alpha-
synuclein levels were not significantly different
compared with controls, but levels in PSP were
higher than in Parkinson’s disease [25
&&]. CSF total
tau and phosphorylated tau levels were not signifi-
cantly different in PSP and CBD compared with
controls in a large study on patients with dementia
[27
&], but was increased in MSA and CBD compared
with Parkinson’s disease with no significant change
in PSP in another study [25
&&]. Ab42 did not differ
significantly between controls and Parkinson’s dis-
ease, MSA, PSP, and CBD [25
&&].
Further studies have investigated a combination
of proteins. Mollenhauer et al. [24] found that CSF
mean alpha-synuclein levels and not total tau or
Ab42 levels differentiated Parkinson’s disease and
MSA from neurological controls (70% sensitivity,
53% specificity), whereas a combination of alpha-
synuclein, tau protein, and age discriminated
between synucleinopathies and neurological con-
trols and Alzheimer’s disease [area under the
curve (AUC) 0.908]. Moreover, a combination of
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alpha-synuclein and phosphorylated tau/total tau
could differentiate Parkinson’s disease from MSA
with a sensitivity of 90% and a specificity of 71%
in another study [28]. Neurofilament light chain
(NFL) as a biomarker of axonal degeneration was
increased in atypical parkinsonian syndromes and
differentiated from Parkinson’s disease (AUC of
0.93), which has been confirmed in another study
[29]. The Flt3 ligand, a cytokine that acts as a neuro-
trophic and antiapoptotic factor in CNS, could
alone differentiate between Parkinson’s disease
and MSA with a sensitivity of 99% and a specificity
of 95% [28]. All these promising approaches need
large prospective cohorts of early cases to be con-
firmed and validated.
Other approaches include the ‘-omics’
(genomics, transcriptomics, proteomics, metabolo-
mics), but less research has been done in atypical
parkinsonian disorders in this direction [30
&&]. One
study applied a proteomic profiling strategy for
parkinsonian diseases using mass spectrometry
analysis for magnetic-bead-based enrichment of
CSF peptides/proteins and subsequent multivariate
statistical analysis on 37 Parkinson’s disease
patients, 32 MSA patients, and 26 patients with
other neurological diseases as controls. Receiver
operating characteristics proved that the peak of
m/z 6250 was the most important to differentiate
MSA from Parkinson’s disease, especially in the early
stages of the disease; however, these results await
confirmation from further studies [31]. Undoubt-
edly, these methods are promising for the future
identification of biomarkers, which are urgently
needed in these disorders.
UPDATE ON TREATMENTS
Although there are still no treatments available for
the sporadic atypical parkinsonian conditions,
important efforts have been done in recent years,
which, even if not proven effective clinically, will
certainly guide further research. A randomized,
placebo-controlled clinical trial to assess the effects
of treatment with the monoamine oxidase-B inhibi-
tor rasagiline (1mg/day) for 48 weeks in 174 patients
withpossibleorprobableMSA-Parkinsonism type,in
39 sites in 12 countries, found no significant differ-
ence in progression in the total Unified Multiple
System Atrophy Rating Scale (UMSARS) score
between the verum and placebo groups [32]. A
single-arm, single-center, open-label pilot trial eval-
uated monthly infusions of 0.4g/kg intravenous
immunoglobulin for 6 months in seven patients as
an anti-inflammatory approach, and found signifi-
cantly increased SBP and improved UMSARS part I
(activities of daily living) and II (motor functions);
verification in a controlled study was proposed [33].
Lee et al. [34] compared 30–50 intraarterial or
intravenous injections of autologous mesenchymal
stem cells (MSCs, 4 10
7/injection) vs. placebo in
33 patients with probable MSA-cerebellar type and
suggested that the MSC group had a smaller increase
in total and part II UMSARS scores from baseline
throughouta360-dayfollow-upperiod;asthemech-
anism of action of this intervention remains unclear,
a careful experimental and clinical re-evaluation of
these findings should be considered [34].
In regard to PSP, a multinational phase 2/3
randomized, double-blind, placebo-controlled trial
enrolled 313 participants, to be treated with 30mg
davunetide or placebo twice daily for 52 weeks at
47 sites, and found no significant effect on the
co-primary outcome measures, the Progressive
Supranuclear Palsy Rating Scale (PSPRS) and the
Schwab and England Activities of Daily Living
(SEADL) (Press release December 18, 2012 by Allon
Therapeutics, www.allontherapeutics.com). An
open label pilot trial of lithium, an inhibitor of
glycogen synthase kinase-3 (GSK-3), in individuals
with PSP or CBD (ClinicalTrials.gov Identifier
NCT00703677) recruited 17 patients and was
stoppedprematurely because the majority of partici-
pants did not tolerate the study drug. A multina-
tional, phase II, double-blind, placebo-controlled
trial enrolled 142 patients with PSP, who were
treated orally with tideglusib (600 or 800mg p.d.),
also a GSK-3 inhibitor, or placebo for 1 year. There
were no significant differences between the high
dose,lowdose,andeitherdosegroupsvs.theplacebo
group in the primary clinical outcome measures. A
subsetof37patientsunderwentbaselineand52-week
MRI; this substudy demonstrated significantly
reduced global brain atrophy in tideglusib-treated
patients [35]. The effect of GSK-3 inhibition in PSP
thus warrants further investigation.
CONCLUSION
The knowledge obtained recently on atypical par-
kinsonian conditions points out clearly what are the
majordeficitsinthisfield,which,comparedtoother
neurodegenerative diseases, lacks major advances in
terms of early diagnosis and treatments. With the
expanding phenotypical spectrum of atypical par-
kinsonian conditions, the early identification of
patients has become difficult; thus, new clinical
criteria are being currently revised. The inability
of conventional methods such as MRI to identify
these disorders earlier and better than clinicians,
and the recent failure of promising therapeutic
compounds based on rational therapeutic hypo-
theses [36] highlight the fact that the lack of
Movement disorders
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biomarkers is probably the greatest limitation for
developing treatments for these disorders. Thus,
current and future research in this direction will
be crucial.
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